PE20210158A1 - Composiciones y metodos para tratar el estrenimiento grave - Google Patents

Composiciones y metodos para tratar el estrenimiento grave

Info

Publication number
PE20210158A1
PE20210158A1 PE2020001407A PE2020001407A PE20210158A1 PE 20210158 A1 PE20210158 A1 PE 20210158A1 PE 2020001407 A PE2020001407 A PE 2020001407A PE 2020001407 A PE2020001407 A PE 2020001407A PE 20210158 A1 PE20210158 A1 PE 20210158A1
Authority
PE
Peru
Prior art keywords
extress
compositions
methods
pyridin
treat severe
Prior art date
Application number
PE2020001407A
Other languages
English (en)
Inventor
Brian K Hubbard
Michael H Serrano-Wu
Original Assignee
Anji Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anji Pharmaceuticals Inc filed Critical Anji Pharmaceuticals Inc
Publication of PE20210158A1 publication Critical patent/PE20210158A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripcion proporciona metodos para tratar o prevenir la disfuncion gastrointestinal, especialmente el estrenimiento. Este metodo comprende administrar al sujeto una cantidad terapeuticamente eficaz de un inhibidor de DGAT1, con lo cual se reducen los sintomas de la disfuncion gastrointestinal. Este inhibidor de diacilglicerol O-aciltransferasa (DGAT1) se selecciona entre acido trans-4-(4-(5-((6-(trifluorometil)piridin-3-il)amino)piridin-2-il)fenil)ciclohexano acetico; acido 3-(4-(6-(5-(4-metoxifenil)-1,3,4-oxadiazol-2-il)-1Hbenzo[d]imidazol-2-il)-3,5-dimetilfenil)-2,2-dimetilpropanoico o un anticuerpo.
PE2020001407A 2018-03-16 2019-03-15 Composiciones y metodos para tratar el estrenimiento grave PE20210158A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862644033P 2018-03-16 2018-03-16
PCT/US2019/022499 WO2019178492A1 (en) 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation

Publications (1)

Publication Number Publication Date
PE20210158A1 true PE20210158A1 (es) 2021-01-26

Family

ID=67904819

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001407A PE20210158A1 (es) 2018-03-16 2019-03-15 Composiciones y metodos para tratar el estrenimiento grave

Country Status (16)

Country Link
US (3) US11224590B2 (es)
EP (1) EP3765012A4 (es)
JP (1) JP7527984B2 (es)
KR (1) KR20200136428A (es)
CN (1) CN111936137B (es)
AU (1) AU2019234956A1 (es)
BR (1) BR112020018790A2 (es)
CA (1) CA3093970A1 (es)
EA (1) EA202092190A1 (es)
IL (1) IL277332B1 (es)
MX (1) MX2020009604A (es)
PE (1) PE20210158A1 (es)
PH (1) PH12020551468A1 (es)
SG (1) SG11202008971VA (es)
TW (1) TWI704917B (es)
WO (1) WO2019178492A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019234956A1 (en) 2018-03-16 2020-10-01 Anji Pharmaceuticals Inc. Compositions and methods for treating severe constipation
KR20220052459A (ko) 2020-10-21 2022-04-28 주식회사 엘지에너지솔루션 전극 탭 고정부를 포함하는 용접장치 및 이를 이용한 전극 탭 용접 방법

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3225997A (en) 1996-05-30 1998-01-05 Trustees Of Columbia University In The City Of New York, The Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
DE69939426D1 (de) 1998-06-24 2008-10-09 David Gladstone Inst Diacylglycerin o-acyltransferase
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
US6635640B2 (en) 2000-06-30 2003-10-21 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
CA2514473C (en) 2002-11-22 2008-05-27 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
WO2005072740A2 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
TW200606137A (en) 2004-07-02 2006-02-16 Sankyo Co Urea derivatives
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
JP2008516978A (ja) 2004-10-15 2008-05-22 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満症の処置のためのビフェニル−４−イル−カルボニルアミノ酸誘導体の製造および使用
US7795283B2 (en) 2004-12-14 2010-09-14 Astrazeneca Ab Oxadiazole derivative as DGAT inhibitors
CA2605300A1 (en) 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
CN101595532B (zh) 2005-06-28 2013-07-31 E.I.内穆尔杜邦公司 缓冲组合物
AU2007245059B2 (en) 2006-03-31 2011-07-28 Novartis Ag New compounds
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
US8324241B2 (en) 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
RU2012145950A (ru) * 2010-03-30 2014-05-10 Новартис Аг Применения ингибиторов dgati
EP2556049A1 (en) * 2010-04-08 2013-02-13 MediciNova, Inc. Methods and compositions for the treatment of irritable bowel syndrome
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013130370A2 (en) * 2012-03-01 2013-09-06 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
MX2015002210A (es) * 2012-08-29 2015-05-08 Salix Pharmaceuticals Inc Composiciones laxantes y metodos para tratar estreñimiento y enfermedades y condiciones gastrointestinales relacionadas.
RU2016132340A (ru) * 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулина аспарта
AU2019234956A1 (en) 2018-03-16 2020-10-01 Anji Pharmaceuticals Inc. Compositions and methods for treating severe constipation

Also Published As

Publication number Publication date
AU2019234956A1 (en) 2020-10-01
US20220193044A1 (en) 2022-06-23
KR20200136428A (ko) 2020-12-07
PH12020551468A1 (en) 2021-09-01
JP2021518431A (ja) 2021-08-02
TW201944995A (zh) 2019-12-01
MX2020009604A (es) 2023-01-25
US11819495B2 (en) 2023-11-21
CN111936137B (zh) 2023-09-08
CN111936137A (zh) 2020-11-13
EP3765012A4 (en) 2021-12-15
IL277332A (en) 2020-10-29
CA3093970A1 (en) 2019-09-19
IL277332B1 (en) 2024-09-01
US20190282549A1 (en) 2019-09-19
US20240293376A1 (en) 2024-09-05
WO2019178492A1 (en) 2019-09-19
TWI704917B (zh) 2020-09-21
BR112020018790A2 (pt) 2020-10-13
SG11202008971VA (en) 2020-10-29
JP7527984B2 (ja) 2024-08-05
EA202092190A1 (ru) 2020-11-19
US11224590B2 (en) 2022-01-18
EP3765012A1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
PE20220141A1 (es) Inhibidores de la proteina tirosina fosfatasa
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
PE20060823A1 (es) Compuestos de arilsulfonamida como moduladores de receptores cck1/cck2
PE20221336A1 (es) Compuestos triciclicos sustituidos
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
JP7217752B2 (ja) Ａｃｓｓ２阻害剤およびその使用方法
AR067886A1 (es) Derivados de acido azabifenilaminobenzoico
PE20161368A1 (es) Inhibidores de diacilglicerol aciltranferasa 2
PE20210158A1 (es) Composiciones y metodos para tratar el estrenimiento grave
EA200500257A1 (ru) Производные хинолина и их применение в качестве микобактериальных ингибиторов
PE20081836A1 (es) Derivados de piperidina como inhibidores de la sintasa de acido graso
EA201001414A1 (ru) Производные азетидина и их применение
PE20140207A1 (es) Composiciones y metodos para modular el fxr
NO20080942L (no) Amino-5-[4-(difluormetoksy)-fenyl]-5-fenylimidazolonforbindelser som inhibitorer av beta-sekretase (BACE)
PE20231652A1 (es) Nuevo inhibidor de la secrecion de acido y uso del mismo
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
NO20092692L (no) MAPK/ERK kinaseinhibitorer
CO4910169A1 (es) Pirazoles como inhibidores de la fosfolipasa secretoria no pancreatica a2 humana
PE20080843A1 (es) Inhibidores de renina y metodo para su utilizacion
EA201100189A1 (ru) Гетероарильные производные в качестве ингибиторов dgat1
PE20161369A1 (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona
EA022420B1 (ru) Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5)
AU2009273259B2 (en) Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
JP2008534541A5 (es)